Loading...
Among the many drugs that interact with ritonavir-boosted protease-inhibitor (PI) regimens are inhaled preparations of fluticasone, whose plasma levels skyrocket when the drug is coadministered with ritonavir in pharmacokinetic studies. Reports of adrenal suppression when fluticasone and ritonavir are combined in clinical practice support the need to find alternate agents for managing seasonal allergies and asthma.
Researchers evaluated the pharmacokinetics of inhaled beclomethasone combined with ritonavir or darunavir/ritonavir in healthy HIV-negative volunteers. Compared with participants who received only beclomethasone, those who added ritonavir (100 mg twice daily) experienced modest, but statistically significant, 1.5- to 2-fold increa…